22 results about "Viral Myocarditis" patented technology

The invention belongs to the field of biological medicine industry, and discloses a peripheral blood marker and system for identifying the severity of viral myocarditis or coronary artery stenosis. The inventor finds for the first time that the average value of LRG1 in blood is not obviously changed compared with that of a normal person when mild and moderate myocarditis and microcirculation angina pectoris with normal coronary artery or coronary artery stenosis smaller than 10% exist, and the blood LRG1 is obviously increased when the coronary artery stenosis of the coronary heart disease exceeds 70%; when severe myocarditis occurs, the blood LRG1 is also obviously increased, so that the increase of the blood LRG1 is a blood marker for patients with severe myocarditis or severe coronary artery lesion, and the blank that blood indexes are lacked in the prior art to prompt the patients to have severe coronary artery stenosis is filled. By detecting the LRG1 content of the peripheral blood and combining with other conventional examinations, the severity of myocarditis or coronary stenosis can be simply, accurately and quickly distinguished, and a corresponding basis is provided for subsequent accurate treatment.

The invention discloses application of piperlongumine in preparation of a medicine for treating virus-induced myocardial fibrosis. According to the application, an in-vivo myocardial fibrosis model is constructed by infecting a BALB / c mouse with a CVB3 virus, and meanwhile, an in-vitro cell model for proliferation and differentiation of primary myocardial fibroblasts is constructed by inducing TGF-beta1. Results prove that when the piperlongumine is applied to the acute stage (1-14 days), the chronic stage (14-28 days) and the whole course (1-28 days) of the viral myocarditis, the myocardial fibrosis of the viral myocarditis can be remarkably improved, the cardiac function is improved, and the curative effect of the piperlongumine applied to the whole course is superior to that of the piperlongumine applied to the acute stage and the chronic stage; the specific mechanism is that Smad2 / 3 and p-38 / YAP pathways jointly play a role in inhibiting myocardial fibrosis.

This invention provides a traditional Chinese medicine compound for treating viral myocarditis, belonging to the field of traditional Chinese medicine pharmaceutical technology. The compound consists of Forsythia suspensa, Fagopyrum dibotrys, Pseudostellaria heterophylla, Rhodiola rosea, Citrus medica, Allium macrostemon, Poria cocos, Gynostemma pentaphyllum, Salvia miltiorrhiza, Dalbergia odorifera, Cynanchum paniculatum, and Valeriana. This traditional Chinese medicine compound exhibits significant protective effects against viral myocarditis, specifically by significantly reducing damage to H9c2 cardiomyocytes caused by CVB3 virus. Its mechanism of action is closely related to downregulating the expression of inflammatory factors TNF-α and IL-6 and inhibiting the inflammatory response. Simultaneously, within the experimental concentration range, the compound shows no toxicity to cardiomyocytes, demonstrating good biocompatibility. Furthermore, this compound can significantly reduce myocardial tissue damage in a viral myocarditis model mouse by inhibiting the in vivo inflammatory response and regulating oxidative stress imbalance, providing a safe and effective new treatment option for the clinical treatment of viral myocarditis.

The invention discloses application of a vitex negundo prevention preparation in preparation of a medicine for treating new crown sequelae and a preparation method of the vitex negundo prevention preparation, and belongs to the field of medicines. The negundo chastetree fruit prevention preparation is prepared from eleven raw medicinal materials including negundo chastetree fruit, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis, radix bupleuri, radix peucedani, ligusticum wallichii, fructus aurantii, poria cocos, platycodon grandiflorum, liquorice and the like, and has the effects of inducing sweat, dispelling exogenous evils, dispelling wind and clearing damp. The negundo chastetree prevention preparation is an effective formula for treating new crown sequelae, can effectively treat viral myocarditis in the recovery period of new crown patients, and can reduce serum concentration of liver function markers ALT and AST and kidney function markers Cre and BUN, so that liver and kidney functions are effectively protected, inflammatory response of acute respiratory distress syndrome is effectively inhibited, diarrhea is effectively treated, and the curative effect is good. And the traditional Chinese medicine composition has an exact treatment effect on the new crown sequelae.

The invention relates to a preparation method of an S100A6 protein with low endotoxin content, and the preparation method comprises the following steps: connecting an S100a6 gene into a pET-28a vector to obtain a pET-28a-S100a6 plasmid; introducing into Escherichia coli, carrying out induced expression, and centrifuging to obtain thalli containing S100A6 protein; cracking, crushing and centrifugally filtering the thalli to obtain a supernatant; performing nickel column purification and Q column chromatography purification on the supernatant to obtain a protein solution 2; and purifying with a desalting column to obtain the S100A6 protein. According to the preparation method, the endotoxin content lt can be obtained; the S100A6 protein can be used for researching the S100A6 protein or gene-related pathways and mechanisms in a living body, so that an effective scheme is provided for the treatment of diseases. The S100A6 protein can be applied to the research of the S100A6 protein or gene-related pathways and mechanisms in the living body. The invention further provides a regulation and control effect of the S100A6 receptor RAGE in CVB3 viral myocarditis, and a new target spot and a new treatment scheme are provided for development of drugs for treating the CVB3 viral myocarditis.

The invention discloses a construction method of a CAPN1 gene myeloid specific knockout mouse viral myocarditis animal model. The construction method comprises the following steps: carrying out gene identification on a mouse, distinguishing genotypes, extracting genome DNA (Deoxyribonucleic Acid), designing specific primers aiming at a CAPN1 gene and a Lyz2-Cre gene, carrying out PCR (Polymerase Chain Reaction) amplification, and carrying out gel electrophoresis detection on a PCR product; a PCR reaction system comprises extracted DNA, Taq polymerase and dNTPs, a CAPN1flox / flox mouse shows a normal fragment of the CAPN1 gene, a cKO mouse shows deletion of a specific region of the CAPN1 gene, a Lyz2-Cre + mouse shows a band of the Cre gene, and a CAPN1 gene myeloid specific knockout mouse is obtained. The construction of the viral myocarditis animal model by down-regulating the Calpain1 level in the neutrophile granulocyte has important application value.

This invention discloses a drug for preventing and treating myocarditis caused by CVB3 virus and its application, belonging to the field of biomedical technology. This invention discovers an hsa-miR-199a-5p mimic that can be used to prevent and treat myocarditis caused by CVB3 virus. The nucleotide sequence of this hsa-miR-199a-5p mimic is shown in SEQ ID NO.1, and its antisense strand nucleotide sequence is shown in SEQ ID NO.2. This invention reveals that hsa-miR-199a-5p mimics can effectively inhibit viral RNA replication and protein biosynthesis and expression in CVB3, and reduce cell death caused by viral infection. Therefore, hsa-miR-199a-5p plays an important role in regulating and controlling CVB3 replication and protein expression. The use of hsa-miR-199a-5p mimics and / or their antisense strands to prepare anti-CVB3 virus drugs, drugs for the prevention and / or treatment of viral myocarditis, drugs for inhibiting CVB3 viral protein expression, drugs for inhibiting CVB3 viral replication, or drugs for reducing CVB3 virus-induced cell death, as well as the preparation of CVB3 virus detection products and viral myocarditis diagnostic products, all have significant clinical application potential.

The invention belongs to the technical field of biological medicines, and particularly discloses application of rosmarinic acid (RA) in treatment of viral myocarditis caused by group B type 3 coxsackie virus (CVB3). Mouse animal model research finds that the rosmarinic acid can significantly reduce the virus load in CVB3 infected mouse cardiac muscle tissue, and proves that the rosmarinic acid has the effect of inhibiting CVB3 virus replication; meanwhile, the treatment can obviously improve cardiac function impairment caused by CVB3 virus infection and relieve inflammatory response of cardiac muscle tissue, and the release of key inflammatory factors and myocardial injury factors is reduced. The invention provides an experimental basis for treating viral myocarditis by using rosmarinic acid as an anti-CVB3 virus drug.

To provide a bifunctional degrading agent for interleukin-1 receptor-related kinases and its therapeutic use. [Solution] This disclosure provides a bifunctional compound as an IRAK4 degradation agent via the ubiquitin-proteasome pathway, and a method for treating diseases modulated by IRAK4. The compounds of this disclosure or their pharmaceutical compositions are useful as therapeutic agents for treating inflammatory disorders such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, necrotizing enterocolitis, gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases including chronic kidney disease and diabetic kidney disease.

The application provides the technical field of biological medicine, and particularly relates to BAZ2B The application provides application of a gene in preparation of a preparation for regulating viral myocarditis. BAZ2B The gene can be applied in preparation of the preparation for regulating viral myocarditis, and the BAZ2B inhibitor GSK2801 can effectively treat viral myocarditis.

The application discloses a kit for detecting coxsackie virus B3, which comprises: an RNA extraction and reverse transcription system, an MIRA isothermal amplification system, a CRISPR-Cas12a detection system, a test strip, and the like. The kit is convenient to operate, can quickly and sensitively detect coxsackie virus B3 in a biological sample, and is used for improving the diagnosis efficiency of viral myocarditis.

The invention discloses a humanized monoclonal antibody of a beta1-adrenergic receptor as well as a kit and application of the humanized monoclonal antibody. The amino acid sequence of the humanized monoclonal antibody of the beta1-adrenergic receptor is as shown in SEQ ID No.1. The invention further discloses a preparation method of the humanized monoclonal antibody of the beta1-adrenergic receptor. According to the distribution condition of myocardial antigenic determinants, polypeptides of natural antigenic determinants are designed and synthesized to immunize animals to prepare monoclonal antibodies and carry out humanized expression, so that the antibody detection kit is prepared. The kit can be used for auxiliary diagnosis of autoimmune response activation and prognosis judgment of patients with viral myocarditis and dilated cardiomyopathy, and auxiliary establishment of a patient treatment scheme.

The invention belongs to the technical field of biology, and particularly relates to application of PDPN (Podoplanin) in preparation of a medicine for treating viral myocarditis. More specifically, the invention provides a novel immunogenic peptide fragment PDPN-TE12 aiming at PDPN, a coding sequence of the novel immunogenic peptide fragment PDPN-TE12, a pharmaceutical composition containing the novel immunogenic peptide fragment PDPN-TE12, and application of the novel immunogenic peptide fragment PDPN-TE12 in prevention and / or treatment of inflammatory cardiomyopathy such as viral myocarditis. Experimental results show that the polypeptide PDPN-TE12 can significantly relieve myocardial damage of mice with viral myocarditis and inhibit inflammatory cell infiltration and inflammatory cytokine expression, so that the polypeptide PDPN-TE12 can be used as a potential drug for treating viral myocarditis, and a new candidate strategy is provided for precise targeted therapy of the disease.

This invention discloses a drug for viral myocarditis, relating to the field of drug preparation technology. The drug comprises at least one of imperatorin, isochorin, and epicatechin gallate. This drug can effectively inhibit viral replication in myocardial tissue, significantly reduce serum pro-inflammatory factor levels, alleviate inflammatory infiltration, and significantly reduce cell apoptosis, thereby exerting a therapeutic effect on viral myocarditis. This invention solves the problem of the lack of highly effective multi-target viral myocarditis drugs in the prior art.

The invention discloses a humanized monoclonal antibody of an L-type calcium channel as well as a kit and application of the humanized monoclonal antibody, the humanized monoclonal antibody comprises a heavy chain and a light chain, and amino acid sequences of the heavy chain and the light chain are respectively shown as SEQ ID No.1 and SEQ ID No.2; according to the distribution condition of myocardial antigenic determinants, a polypeptide of a natural antigenic determinant, namely an L-type calcium channel antigen, is designed and synthesized, an animal is immunized to prepare a monoclonal antibody, humanized expression is carried out, and the antibody detection kit is prepared from the monoclonal antibody for application. The kit can be used for auxiliary diagnosis of viral myocarditis and dilated cardiomyopathy and auxiliary establishment of a patient treatment scheme.

This disclosure relates, in general, to a process for preparing compounds that are inhibitors of the kinase IRAK4, and to synthetic intermediates prepared thereby. IRAK4 inhibitors may be useful in the treatment of inflammatory and fibrous disorders, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases, including chronic kidney disease and diabetic kidney disease.

The invention provides a traditional Chinese medicine compound for treating viral myocarditis, and relates to the technical field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine compound consists of fructus forsythiae, wild buckwheat, radix pseudostellariae, rhodiola rosea, citron, allium macrostemon, poria cocos, Chinese alpine rush, semen aesculi, lignum dalbergiae odoriferae, radix cynanchi atrati and valerian. The traditional Chinese medicine compound has a remarkable protective effect on viral myocarditis, specifically, the compound can remarkably relieve H9c2 myocardial cell damage caused by CVB3 virus, and the action mechanism of the compound is closely related to down-regulation of expression of inflammatory factors TNF-alpha and IL-6 and inhibition of inflammatory response; meanwhile, within the experimental concentration range, the compound has no toxic effect on myocardial cells and shows good biological safety. Besides, the compound can remarkably relieve myocardial tissue damage of viral myocarditis model mice by inhibiting inflammatory response in vivo and adjusting oxidative stress imbalance, and a safe and effective new treatment scheme is provided for clinical treatment of viral myocarditis.

The invention discloses application of a vitex negundo prevention preparation in preparation of a medicine for treating new crown sequelae and a preparation method of the vitex negundo prevention preparation, and belongs to the field of medicines. The negundo chastetree fruit prevention preparation is prepared from eleven raw medicinal materials including negundo chastetree fruit, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis, radix bupleuri, radix peucedani, ligusticum wallichii, fructus aurantii, poria cocos, platycodon grandiflorum, liquorice and the like, and has the effects of inducing sweat, dispelling exogenous evils, dispelling wind and clearing damp. The negundo chastetree prevention preparation is an effective formula for treating new crown sequelae, can effectively treat viral myocarditis in the recovery period of new crown patients, and can reduce serum concentration of liver function markers ALT and AST and kidney function markers Cre and BUN, so that liver and kidney functions are effectively protected, inflammatory response of acute respiratory distress syndrome is effectively inhibited, diarrhea is effectively treated, and the curative effect is good. And the traditional Chinese medicine composition has an exact treatment effect on the new crown sequelae.

The application discloses use of let-7a-5p in human umbilical cord mesenchymal stem cell exosomes, and relates to the technical field of biological medicines, and has the technical points that the let-7a-5p in the human umbilical cord mesenchymal stem cell exosomes is applied to preparation of a medicine for treating viral myocarditis; the let-7a-5p in the exosomes inhibits CVB3-induced myocardial cell ferroptosis through mediation of SMAD2 to promote a ZFP36 expression path, so that viral myocarditis is treated. The application proves how the let-7a-5p in the human umbilical cord mesenchymal stem cell exosomes relieves the process of CVB3-induced viral myocarditis, and provides a new and effective treatment method according to the mechanism of CVB3-induced viral myocarditis.

The invention belongs to the technical field of medicine. The invention provides a pharmaceutical composition for treating viral myocarditis. The pharmaceutical composition comprises citrulline and arbidol hydrochloride. The combined use of the pharmaceutical composition disclosed by the invention has a remarkable curative effect on viral myocarditis caused by CVB3, and the pharmaceutical composition disclosed by the invention is simple in components, easy to obtain and relatively good in clinical application prospect.

The invention belongs to the technical field of biological medicines, and particularly discloses application of abietic acid (AA) in treatment of viral myocarditis caused by group B type 3 coxsackie virus (CVB3). Mouse animal model research finds that abietic acid can significantly reduce the virus load in CVB3 infected mouse cardiac muscle tissue, and proves that abietic acid has the effect of inhibiting CVB3 virus replication; meanwhile, the treatment can obviously improve cardiac function impairment caused by CVB3 virus infection and relieve inflammatory response of cardiac muscle tissue, and the release of key inflammatory factors and myocardial injury factors is reduced. The invention provides an experimental basis for treating viral myocarditis by using abietic acid as an anti-CVB3 virus drug.

The present invention discloses the application of a Jingfang preparation in the preparation of a drug for treating the sequelae of the new crown and its preparation method, and belongs to the field of medicine. The Jingfang preparation is made of eleven raw medicinal materials such as Schizonepeta tenuifolia, Saposhnikovia divaricata, Notopterygium wilfordii, Angelica dahurica, Bupleurum chinense, Peucedanum chinense, Chuanxiong, Fructus Aurantii Immaturus, Poria cocos, Platycodon grandiflorum, and Licorice, and has the effects of diaphoresis, dispelling wind and removing dampness. The Jingfang preparation of the present invention is an effective prescription for treating the sequelae of the new crown, which can effectively treat viral myocarditis in the recovery period of new crown patients, reduce the serum concentrations of liver function markers ALT and AST and kidney function markers Cre and BUN, thereby effectively protecting liver and kidney function, effectively inhibiting the inflammatory response of acute respiratory distress syndrome, and effectively treating diarrhea at the same time, treating both the symptoms and the root cause, and having a definite therapeutic effect on the sequelae of the new crown.